Connecting PBPK experts
Connecting PBPK experts
About us
The International PBPK Nexus was created from a shared belief: physiologically-based pharmacokinetic (PBPK) modelling deserves its own dedicated community and platform.
We bring together researchers, modellers, clinicians, and regulatory scientists from academia, industry, and public institutions worldwide to advance PBPK science, foster collaboration, and support the growth of the field.
Our first conference had :
0
1
2
3
4
5
0
0
+
Attendees
0
1
2
3
4
5
0
0
+
Attendees
0
1
2
0
1
2
3
4
+
Countries
0
1
2
3
4
5
6
M+
Countries
1
0
1
0
1
2
+
Abstracts submitted
0
1
2
3
4
5
6
7
B
Abstracts submitted
About us
The International PBPK Nexus was created from a shared belief: physiologically-based pharmacokinetic (PBPK) modelling deserves its own dedicated community and platform.
We bring together researchers, modellers, clinicians, and regulatory scientists from academia, industry, and public institutions worldwide to advance PBPK science, foster collaboration, and support the growth of the field.
Our first conference had :
0
1
2
3
4
5
0
0
+
Attendees
0
1
2
3
4
5
6
M+
Countries
0
1
2
3
4
5
6
7
B
Abstracts submitted
Our Mission
Our Mission
To advance PBPK modelling through international collaboration, scientific excellence, and an inclusive global community.
Our core values
Our core values
Science
We advance the science of PBPK through rigorous research, open Scientific exchange, around a commitment to excellence and integrity.
Science
We promote rigorous, high-quality science and uphold the highest standards of integrity in research and collaboration.
Science
We advance the science of PBPK through rigorous research, open Scientific exchange, around a commitment to excellence and integrity.
Connection
We bring together scientists, regulators, industry professionals, and academics from around the world to foster collaborations and accelerate innovation.
Connection
We bring together scientists, regulators, industry professionals, and academics from around the world to foster collaborations and accelerate innovation.
Connection
We bring together scientists, regulators, industry professionals, and academics from around the world to foster collaborations and accelerate innovation.
Support
We create opportunities for students, trainees, and scientists at all career stages to learn, contribute, and grow within the PBPK community.
Support
We create opportunities for students, trainees, and scientists at all career stages to learn, contribute, and grow within the PBPK community.
Support
We create opportunities for students, trainees, and scientists at all career stages to learn, contribute, and grow within the PBPK community.
Continuity
We build a lasting international PBPK community that grows, evolves and delivers value beyond any single event, fostering meaningful connections and long-term collaboration.
Continuity
We build a lasting international PBPK community that grows, evolves and delivers value beyond any single event, fostering meaningful connections and long-term collaboration.
Continuity
We build a lasting international PBPK community that grows, evolves and delivers value beyond any single event, fostering meaningful connections and long-term collaboration.
Board Committee
Board Committee
André Dallmann
Scientist Systems Pharmacology at Bayer
André is Head of PK/PD Modeling & Simulation at Pierre Fabre, where he leads a team providing model-informed drug development (MIDD) support across the whole value chain. He holds a PhD from the University of Münster (2017) and has nearly 10 years of industry experience in MIDD with over 60 peer-reviewed publications.
André Dallmann
Scientist for Virtual Patients at Bayer
is a Scientist for Virtual Patients within the Model-Informed Drug Development department at Bayer. He earned his PhD from the University of Münster, Germany, in 2017, and subsequently pursued a postdoctoral fellowship at the University Children’s Hospital in Basel, Switzerland. In 2018, he joined Bayer as a PBPK expert and was elected as a Science Fellow in 2023. Since 2024, he also serves as a full editorial board member of the Journal of Clinical Pharmacology. André has co-authored two book chapters and nearly 60 peer-reviewed articles in collaboration with researchers from academia, industry, and regulatory agencies.
André Dallmann
Scientist Systems Pharmacology at Bayer
André is Head of PK/PD Modeling & Simulation at Pierre Fabre, where he leads a team providing model-informed drug development (MIDD) support across the whole value chain. He holds a PhD from the University of Münster (2017) and has nearly 10 years of industry experience in MIDD with over 60 peer-reviewed publications.
Chara Litou
Principal PBPK Scientist at Certara Predictive Technologies
Chara is a Principal PBPK Scientist in the PBPK Consultancy group at Certara Predictive Technologies. She brings extensive experience across PBPK–PD, DMPK & clinical pharmacology oversight, supporting drug development & regulatory submissions from early discovery to clinical & post-market stages. She's a strong advocate for integrating PBPK modelling with strategic clinical pharmacology to optimize clinical study design & streamline the drug development process.
Chara Litou
Principal PBPK Scientist at Certara Predictive Technologies
Chara is a Principal PBPK Scientist in the PBPK Consultancy group at Certara Predictive Technologies. She brings extensive experience across PBPK–PD, DMPK & clinical pharmacology oversight, supporting drug development & regulatory submissions from early discovery to clinical & post-market stages. She's a strong advocate for integrating PBPK modelling with strategic clinical pharmacology to optimize clinical study design & streamline the drug development process.
Ioannis Loisios-Konstantinidis
Senior Principal Scientist at Novartis
Ioannis is a Senior Principal Scientist in Modeling and Simulation at Novartis and a recognized PBPK expert. He supports drug development from early clinical phases through registration and lifecycle management, leads the Pharmacokinetics and Biopharmaceutics Network, represents Novartis in EFPIA and IQ, and helped secure approvals for asciminib and remibrutinib.
Ioannis Loisios-Konstantinidis
Senior Principal Scientist at Novartis
Ioannis is a Senior Principal Scientist in Modeling and Simulation at Novartis and a recognized PBPK expert. He supports drug development from early clinical phases through registration and lifecycle management, leads the Pharmacokinetics and Biopharmaceutics Network, represents Novartis in EFPIA and IQ, and helped secure approvals for asciminib and remibrutinib.
Kelly Turton
Events Manager at Certara Predictive Technologies
Kelly while not a Scientist per se, she has certainly organised (and listened to!) her fair share of events over the years whilst collating a wealth of conference experience along the way! Kelly has worked with Certara Predictive Technologies (CPT) for over 20 years organising conferences, exhibitions, and workshops worldwide. Kelly has been a familiar face at over 100 Certara Predictive Technologies events assisting with logistics, travel and accessing the CPT Simulator.
Kelly Turton
Events Manager at Certara Predictive Technologies
Kelly while not a Scientist per se, she has certainly organised (and listened to!) her fair share of events over the years whilst collating a wealth of conference experience along the way! Kelly has worked with Certara Predictive Technologies (CPT) for over 20 years organising conferences, exhibitions, and workshops worldwide. Kelly has been a familiar face at over 100 Certara Predictive Technologies events assisting with logistics, travel and accessing the CPT Simulator.
Loeckie de Zwart
Director at Johnson & Johnson, Innovative Medicine
Loeckie is a director at Johnson & Johnson, Innovative Medicine specialised in PBPK modelling for 27 years in the Preclinical Sciences and Translational Safety department. She leads a team of modelling scientists providing end-to-end PBPK/PD modelling project support ensuring cross-departmental alignment of model predictions.
Loeckie de Zwart
Director at Johnson & Johnson, Innovative Medicine
Loeckie is a director at Johnson & Johnson, Innovative Medicine specialised in PBPK modelling for 27 years in the Preclinical Sciences and Translational Safety department. She leads a team of modelling scientists providing end-to-end PBPK/PD modelling project support ensuring cross-departmental alignment of model predictions.
Maxime Le Merdy
Director, Scientific Product Enablement at Simulations Plus
Maxime is Director of Scientific Product Enablement at Simulations Plus, a leader in pharmaceutical modeling and simulation software. He earned his Pharm.D. from Paris University and Ph.D. in 2022. Previously an FDA postdoctoral fellow, he specialized in PBPK for locally acting drugs, advancing non-oral methodologies and publishing in this field.
Maxime Le Merdy
Director, Scientific Product Enablement at Simulations Plus
Maxime is Director of Scientific Product Enablement at Simulations Plus, a leader in pharmaceutical modeling and simulation software. He earned his Pharm.D. from Paris University and Ph.D. in 2022. Previously an FDA postdoctoral fellow, he specialized in PBPK for locally acting drugs, advancing non-oral methodologies and publishing in this field.
Neil Parrott
M&S Scientist at Roche Pharmaceuticals
Neil is a distinguished scientist in translational modelling and simulation which is a part of Pharmaceutical Sciences at Roche Basel. He is with Roche for 27 years where he is a specialist in physiologically based modelling, supporting projects at the preclinical phase leading to first in human dose predictions and then following projects during discovery and development with multiple other PBPK applications.
Neil Parrott
M&S Scientist at Roche Pharmaceuticals
Neil is a distinguished scientist in translational modelling and simulation which is a part of Pharmaceutical Sciences at Roche Basel. He is with Roche for 27 years where he is a specialist in physiologically based modelling, supporting projects at the preclinical phase leading to first in human dose predictions and then following projects during discovery and development with multiple other PBPK applications.
Youssef Daali
Head of Pharmacological Investigation Unit at Geneva Hospital
Prof. Youssef Daali is Professor at the University of Geneva Faculty of Medicine and heads the Pharmacology and Toxicology Investigation Unit at Geneva University Hospitals. Affiliated with ISPSO, his research advances personalized medicine through drug metabolism, pharmacokinetics, pharmacogenetics, and pharmacometrics. He has national and international recognition and holds professional memberships.
Youssef Daali
Head of Pharmacological Investigation Unit at Geneva Hospital
Prof. Youssef Daali is Professor at the University of Geneva Faculty of Medicine and heads the Pharmacology and Toxicology Investigation Unit at Geneva University Hospitals. Affiliated with ISPSO, his research advances personalized medicine through drug metabolism, pharmacokinetics, pharmacogenetics, and pharmacometrics. He has national and international recognition and holds professional memberships.
Loïc Fässler
Attorney at Espace Legal, Switzerland
Loïc Fässler
Attorney at Espace Legal, Switzerland
Become a Member
Become a Member